The FDA has classified as Class II an ongoing recall of compounded semaglutide from Apollo Care, LLC, dated 19 August 2026, covering multiple vial presentations. The defect is particulate matter in the product, identified as a nylon or polyamide and a silk or proteinaceous-type material. Class II means exposure may cause temporary or medically reversible harm, with serious harm unlikely.
The presentations tell you what kind of product this is: multi-dose sterile vials at 1 mg/mL, 4.5 mg/mL and 5 mg/mL, several with added glycine, in volumes from 1.5 to 5 mL. None of that corresponds to a licensed pen. This is a compounded product, made outside the approved manufacturing chain, and the finding is about that chain rather than about semaglutide.
The clinical use of it is in the history. Patients describe their treatment by drug name, not by supply route, and someone drawing up from a vial is not using the licensed product no matter what they call it. Ask what the drug comes in and what strength is on the label. This is a US action against a US compounder with no CDSCO counterpart; the equivalent exposure in Indian practice is grey-market and counterfeit supply rather than compounding.
- Ask GLP-1 users to show you the device - a vial and syringe is a different supply chain from a pen
- Record the labelled concentration; anything other than licensed pen strengths is worth querying
- Ask about injection-site inflammation or unexplained local reactions in anyone using vialled product
- Recalculate the dose if a patient moves between vialled and pen product
- Report suspected substandard or counterfeit product through the national pharmacovigilance route
Why it matters
It is the compounding route that failed, not the molecule - and patients buying outside the licensed chain usually cannot tell you which they hold.
Don't overread it
A recall of one compounder's product is not a safety signal for licensed semaglutide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free